IPD has been a darling of the analysts but to date has really disapointed in sales growth of the L-Dex system and therefore its share price.
http://www.*.com.au/23-australian-biotech-stocks-to-watch-this-year-2014-2
For eg. Scott Power of Morgans has this on his high conviction list and Bioshares have tipped it.
We know Category 1 coding in the US should boost sales growth through direct reimbursement but how much? And clinical trials have been going for ever it seems to prove the economics of pre-emptive testing.
Give lacklustre performance to date makes it really tough to average down. Perhaps closer to the end of the year if we continue to track sideways?
- Forums
- ASX - By Stock
- Ann: International Post-approval Clinical Trial commences
IPD has been a darling of the analysts but to date has really...
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IPD (ASX) to my watchlist
|
|||||
Last
4.7¢ |
Change
-0.001(2.08%) |
Mkt cap ! $95.08M |
Open | High | Low | Value | Volume |
4.9¢ | 4.9¢ | 4.5¢ | $230.9K | 5.021M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 90000 | 4.6¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
4.8¢ | 2700 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 90000 | 0.046 |
1 | 145000 | 0.045 |
2 | 412899 | 0.044 |
3 | 500000 | 0.043 |
3 | 341830 | 0.042 |
Price($) | Vol. | No. |
---|---|---|
0.048 | 2700 | 1 |
0.049 | 100000 | 1 |
0.050 | 34000 | 2 |
0.051 | 106000 | 2 |
0.052 | 192812 | 1 |
Last trade - 16.10pm 05/09/2024 (20 minute delay) ? |
Featured News
IPD (ASX) Chart |